CN113631580A - 抗her2的双特异性抗体及其应用 - Google Patents

抗her2的双特异性抗体及其应用 Download PDF

Info

Publication number
CN113631580A
CN113631580A CN202080011381.7A CN202080011381A CN113631580A CN 113631580 A CN113631580 A CN 113631580A CN 202080011381 A CN202080011381 A CN 202080011381A CN 113631580 A CN113631580 A CN 113631580A
Authority
CN
China
Prior art keywords
seq
bispecific antibody
heavy chain
light chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080011381.7A
Other languages
English (en)
Other versions
CN113631580B (zh
Inventor
王征
徐云霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Baoji Pharmaceutical Co ltd
Original Assignee
Shanghai Baoji Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Baoji Pharmaceutical Co ltd filed Critical Shanghai Baoji Pharmaceutical Co ltd
Publication of CN113631580A publication Critical patent/CN113631580A/zh
Application granted granted Critical
Publication of CN113631580B publication Critical patent/CN113631580B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供一种抗HER2的双特异性抗体，其包括分别用于识别HER2的胞外结构域II和胞外结构域IV的第一蛋白功能区和第二蛋白功能区，所述第一蛋白功能区包括第一重链和轻链，所述第二蛋白功能区包括第二重链和轻链。还提供包括所述双特异性抗体的药物组合物和它们的用途。所述的双特异性抗体和含其的药物组合物可用于癌症的治疗。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202080011381.7A 2019-02-03 2020-02-03 抗her2的双特异性抗体及其应用 Active CN113631580B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101090084 2019-02-03
CN201910109008 2019-02-03
PCT/CN2020/074171 WO2020156555A1 (zh) 2019-02-03 2020-02-03 抗her2的双特异性抗体及其应用

Publications (2)

Publication Number Publication Date
CN113631580A true CN113631580A (zh) 2021-11-09
CN113631580B CN113631580B (zh) 2024-07-02

Family

ID=

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244403A1 (en) * 2004-03-24 2005-11-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
CN105829347A (zh) * 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法
CN105820251A (zh) * 2015-01-08 2016-08-03 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
WO2018191188A1 (en) * 2017-04-09 2018-10-18 Xiao Shouhua Biparatopic and multiparatopic antibodies with common light chain and method of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244403A1 (en) * 2004-03-24 2005-11-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
CN105829347A (zh) * 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法
CN105820251A (zh) * 2015-01-08 2016-08-03 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
US20190031782A1 (en) * 2015-01-08 2019-01-31 Suzhou Alphamab Co., Ltd Bispecific antibody or antibody mixture with common light chains
WO2018191188A1 (en) * 2017-04-09 2018-10-18 Xiao Shouhua Biparatopic and multiparatopic antibodies with common light chain and method of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李文丽等: "双特异性抗体在肿瘤治疗中的研究", 《生命的化学》, no. 06, pages 18 - 23 *
颜丽萍等: "联合使用曲妥珠单抗和帕妥珠单抗在乳腺癌患者中心脏毒性的Meta分析", 《广西医科大学学报》, no. 05, pages 76 - 80 *

Also Published As

Publication number Publication date
EP3988574A9 (en) 2022-08-03
US20220143178A1 (en) 2022-05-12
JP2022527652A (ja) 2022-06-02
EP3988574A1 (en) 2022-04-27
CN111518213A (zh) 2020-08-11
CN111518213B (zh) 2024-05-28
WO2020156555A1 (zh) 2020-08-06
EP3988574A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
CN111518213B (zh) 抗her2的双特异性抗体及其应用
EP2829552B1 (en) Bispecific chimeric proteins with DARPin-molecules
JP6124377B2 (ja) 新規抗ｄｒ５抗体
CN106459212B (zh) 结合erbb-2和erbb-3的抗体
JP5752687B2 (ja) Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用
CN111995685B (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
CN111196856A (zh) 抗her2/pd1双特异性抗体
US20200291130A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
CN113754775A (zh) 一种抗pd-l1和her2的双特异性抗体
CN113135995B (zh) 抗her3单克隆抗体及其应用
Richter et al. Receptor-targeted cancer therapy
WO2019114793A1 (zh) 一种egfr抗体及其制备方法和应用
KR20180133437A (ko) 신규의 erbb2-표적화 항체
CN113631580B (zh) 抗her2的双特异性抗体及其应用
CN110467676B (zh) 特异性结合egfr的单克隆抗体及其抗癌用途
CN110563846B (zh) 一种特异性结合egfr的单克隆抗体及其抗癌用途
AU2018377764B2 (en) Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
CN114539413A (zh) 结合her2的多价双特异性抗体、其制备方法和用途
JP6502619B2 (ja) 標的特異的な細胞膜タンパク質除去用組成物
CN116284427A (zh) 抗muc17/cd3双特异性抗体、其制备方法及用途
CN116102649A (zh) 抗cldn18.2单克隆抗体及其应用
CN117247457A (zh) 靶向her2和pd-l1的双特异性抗体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 28 Luoxin Road, Baoshan District, Shanghai, 201908

Applicant after: Shanghai Baoji Pharmaceutical Co.,Ltd.

Address before: 200942 room a1002, building 3, No. 2288, Shitai Road, Baoshan District, Shanghai

Applicant before: Shanghai Baoji Pharmaceutical Co.,Ltd.

GR01 Patent grant